The EARLY TAVR trial, colchicine after MI, and the TRISCEND II trial of tricuspid valve replacement are the topics John Mandrola, MD, covers in this week’s podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I. Early TAVR
- EARLY TAVR https://www.acc.org/latest-in-cardiology/clinical-trials/2024/10/24/14/42/early-tavr
- Rationale https://doi.org/10.1016/j.ahj.2023.11.019
- AVATAR https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.121.057639
- RECOVERY https://www.nejm.org/doi/full/10.1056/NEJMoa1912846
- FAME 2 https://www.nejm.org/doi/full/10.1056/NEJMoa1205361
- Rajkumar; Faith Healing in Unblinded Trials https://pubmed.ncbi.nlm.nih.gov/29530888/
- PARTNER 3 trial https://www.nejm.org/doi/full/10.1056/NEJMoa2307447
- EARLY TAVR: A Positive Trial That Fails to Inform Clinical Decisions https://www.medscape.com/viewarticle/early-tavr-positive-trial-fails-inform-clinical-decisions-2024a1000kec
II. Colchicine
- Meta-analysis https://doi.org/10.1016/j.eclinm.2024.102835
- Clear-Synergy Rationale https://pubmed.ncbi.nlm.nih.gov/38936755/
- COLCOT (post MI) https://www.nejm.org/doi/full/10.1056/NEJMoa1912388
- LoDoCo (Chronic CAD) https://www.nejm.org/doi/full/10.1056/NEJMoa2021372
-
III. TRISCEND II Trial
- TRISCEND II Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2401918
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
